ASTRO Issues New Clinical Guideline on Radiation Therapy for Adult Patients With Soft-Tissue Sarcoma

Get Permission

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) published by Kilian E. Salerno, MD, and colleagues in Practical Radiation Oncology provides guidance on the use of radiation therapy to treat adult patients with soft-tissue sarcomas. Recommendations outline optimal radiation dosing, techniques, and treatment planning for patients with localized, operable soft-tissue sarcoma of the trunk and extremities, with a focus on preserving long-term functionality through individualized care. The guideline additionally addresses the role of radiation therapy for retroperitoneal sarcoma.

More About Soft-Tissue Sarcoma Management

While soft-tissue sarcomas are rare—accounting for approximately 1% of adult malignancies—they are potentially lethal tumors that comprise more than 50 different subtypes. These tumors form in the body's connective tissues, such as the muscles, blood vessels, fat, or nerves, and they can occur throughout the body, including the hands or feet, where more common carcinomas generally do not grow.

Management of soft-tissue sarcomas requires nuanced and coordinated care from a multidisciplinary team of surgical, orthopedic, medical, and radiation oncologists, as well as specialized pathologists and radiologists. Because not all patients are able to receive treatment at high-volume centers where physicians have experience managing these rare tumors, comprehensive guidelines are essential to guide treatment decisions.

"Management of soft-tissue sarcoma can be complicated, with the potential for poor outcomes and significant morbidity if treated suboptimally. The addition of radiation therapy to surgery reduces the chance of local recurrence," said Dr. Salerno, who is Vice Chair of the Guideline Task Force and a radiation oncologist at the National Cancer Institute. "This guideline stresses the importance of multidisciplinary input prior to initiation of treatment and provides detailed recommendations on indications for radiation therapy, dose, and planning techniques. ASTRO developed this guideline to provide clear guidance on the role of radiation therapy in patient-centered, multidisciplinary oncologic care."

Kilian E. Salerno, MD

Kilian E. Salerno, MD

B. Ashleigh Guadagnolo, MD, MPH

B. Ashleigh Guadagnolo, MD, MPH

Standard treatment for soft-tissue sarcoma involves surgical resection, with radiation therapy for patients who are at increased risk of recurrence. In the past, radiation generally followed surgery, but this paradigm has shifted to favor preoperative radiation therapy. While local recurrence rates are similarly low with preoperative and postoperative approaches, long-term side effects vary depending on when radiation is given relative to surgical resection.

"When radiation is indicated, it generally should be given before surgery because the long-term side effects are less severe," said B. Ashleigh Guadagnolo, MD, MPH, Chair of the Guideline Task Force and a Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center. "The side effects of preoperative radiation therapy can be serious, but they are reversible. Postoperative radiation therapy side effects, however, are in many cases permanent because more radiation dose is required when given after surgery, and it often needs to be given to a larger area of the body."

"Research on patterns of care in the United States indicates that most radiation therapy for soft-tissue sarcomas continues to be given postoperatively, however. Therefore, there is a need for clear clinical guidance on modern treatment approaches that can have less impact on patients' long-term quality of life," she added.

Key Guideline Recommendations

Recommendations in the guideline address patient selection for radiation therapy and outline best practices for dosing, sequencing, planning, and image guidance for extremity and superficial truncal soft-tissue sarcomas, as well as for retroperitoneal sarcomas, which offer a worse prognosis than those in the extremities. The guideline also calls attention to the fundamental role that cooperation between the multidisciplinary care team has in the design and delivery of patient care.

Key recommendations are as follows:

  • Radiation therapy is recommended for patients with primary, localized extremity and truncal soft-tissue sarcomas who are at increased risk of local recurrence, based on multidisciplinary evaluation of the tumor's pathology, location, and size; final or expected surgical margins; and other factors that are detailed in the guideline. Radiation therapy generally is not recommended for patients at low risk of local recurrence.
  • For patients where surgery and radiation therapy are indicated, preoperative radiation therapy is recommended. Postoperative radiation therapy is recommended only in specific clinical circumstances, such as the discovery of unanticipated adverse pathologic features following oncologic resection or unplanned excision, or when the risk of wound-healing complications outweighs the risk of long-term, permanent side effects. The guideline also includes treatment algorithms for initial local management and local management following an unplanned excision.
  • For patients with primary localized retroperitoneal sarcomas, the routine use of radiation therapy in addition to oncological resection is conditionally not recommended. Selective use of radiation therapy may be considered for patients with retroperitoneal sarcomas at high risk of local recurrence. When radiation therapy is indicated in these select cases, preoperative radiation is preferred.
  • The guideline addresses optimal dosing, fractionation, target delineation, and delivery techniques for preoperative and postoperative radiation therapy, including recommendations for image guidance and patient positioning, with specific attention to patients' long-term functional outcomes.

About the Guideline

The guideline was based on a systematic literature review of articles published from January 1980 through September 2020. The multidisciplinary task force included radiation, medical, orthopedic, and surgical oncologists; a radiation oncology resident; a pathologist; a medical physicist; and a patient representative. The guideline was developed in collaboration with ASCO, the Musculoskeletal Tumor Society, and the Society of Surgical Oncology, and endorsed by the Canadian Association of Radiation Oncology, the European Society for Radiotherapy and Oncology, the Musculoskeletal Tumor Society, the Royal Australian and New Zealand College of Radiologists, and the Society of Surgical Oncology.

Disclosure: For full disclosures of the study authors, visit

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.